Research, develop, and manufacture pharmaceutical products primarily focused on ophthalmology. Now — the numbers.
This is an established company with proven profits.
No real growth (2% a year). Red columns mark years that ended in a loss.
If every debt were paid off today, $316.2M would still be left in the vault — a solid cushion for hard times.
The market pays 17.2× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades below its recent peak — about 10% off the top. A pullback, not a collapse.
There is $542.4M in the vault; even if every debt were paid off, $316.2M would remain.
It pays out $0.25 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Against everything we grade, SNPHF lands near the bottom. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SNPHF does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Not covered, because the filings we hold do not carry it: the revenue breakdown.